Margaret Z. Borok

Dr. Margaret Z. Borok


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MBMargaret Z. Borok
Margaret Z. Borok
SFSuzanne Fiorillo
Suzanne Fiorillo
IGIvy Gudza
Ivy Gudza
BPBeverly Putnam
Beverly Putnam
BNBuxton Ndemera
Buxton Ndemera
TCThomas B. Campbell
Thomas B. Campbell
Background. The usefulness of plasma human herpesvirus 8 (HHV-8) DNA as a marker of response to treatment for acquired immunodeficiency syndrome-asso

28 March 2014 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
JGJacob Gray
Jacob Gray
GFGolden T Fana
Golden T Fana
TCThomas B Campbell
Thomas B Campbell
JHJames G Hakim
James G Hakim
MBMargaret Z. Borok
Margaret Z. Borok
EAEva M Aagaard
Eva M Aagaard
In 2010, in the midst of the human immunodeficiency virus (HIV) epidemic in Zimbabwe, 69% of faculty positions in the Department of Medicine of the University of Zimbabwe College of Health Sciences (UZ-CHS) were vacant. To address the ongoing need to train highly skilled HIV clinicians with only a limited number of faculty, we developed and implemented a course for final-year medical students focused on HIV care using team-based learning (TBL) methods.

2 February 2021 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
MMMichalina A Montaño
Michalina A Montaño
MCMaganizo B Chagomerana
Maganizo B Chagomerana
MBMargaret Z. Borok
Margaret Z. Borok
MPMatthew Painschab
Matthew Painschab
TUThomas S Uldrick
Thomas S Uldrick
RIRachel A Bender Ignacio
Rachel A Bender Ignacio

1 January 2014 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MBMargaret Z. Borok
Margaret Z. Borok
NBNaftali Busakhala
Naftali Busakhala
TMTariro Makadzange
Tariro Makadzange
JHJames Hakim
James Hakim
The phenomenon of disproportionately large allocations of global health research resources to relatively limited components of the global health burden is widely acknowledged. Factors contributing to this are explored. The development of a national or regional research agenda is a critical step toward attempting to redress this imbalance. Key areas to be considered are a broad vision, dialogue, and commitment from those stakeholders comprising the “health research triangle”: national policy makers and decision makers, key personnel in both health research and health care, and community representatives. The interdependent roles of human, material, and community resources are further examined.

9 June 2026 in Livers
Verified
Journal Article
Open access
PDF file
TMTinashe Adrian Mazhindu
Tinashe Adrian Mazhindu
VNVincent Nyangwara
Vincent Nyangwara
MMMichalina A. Montaño
Michalina A. Montaño
EMEdith Matsikidze
Edith Matsikidze
OCOnesai Blessing Chihaka
Onesai Blessing Chihaka
NNNtokozo Ndlovu
Ntokozo Ndlovu
Background: Infection with HIV increases the risk of developing hepatocellular carcinoma, and the albumin–bilirubin grade assesses liver function and has been shown to be prognostic. We evaluated the albumin–bilirubin score/grade and the HIV status of hepatocellular carcinoma patients in Zimbabwe and explored the impact on median survival. Methods: A 10-year retrospective observational study of hepatocellular carcinoma patients was conducted at a single tertiary-level cancer center in Harare, Zimbabwe. Survival probabilities were estimated using the Kaplan–Meier method, and differences between groups were compared using the log-rank test and Cox proportional hazards regression. Results: A total of 95 participants were evaluated, of whom 72.6% were male. Most HCC cases were diagnosed using imaging and serum alpha-fetoprotein, with 59% presenting at Barcelona Clinic Liver Cancer stage C or D. Compared with patients who were HIV-negative, patients who were HIV-positive (OR 2.2; 95% CI 1.54–5.26, p = 0.0008) or had an unknown HIV status (OR 4.2; 95% CI 2.2–8; p < 0.0001) had higher odds of being at ALBI grade 3 at the time of HCC diagnosis. ALBI grade 1 patients had better median survival compared to grade 2 and 3 patients, though this result was statistically insignificant (grade 2: HR = 1.45, 95% CI: 0.30–7.13; grade 3: HR = 1.47, 95% CI: 0.28–7.60). Regarding HIV status, median survival was 2.4 months for HIV-positive patients and 2.6 months for HIV-negative patients (p = 0.51); HIV positivity was not significantly associated with median survival (HR = 1.50, 95% CI: 0.46–4.91). Only 30.5% of patients received cancer therapy, all of which was palliative, with no observed survival benefit. Conclusions: The majority of hepatocellular carcinoma patients in Zimbabwe were diagnosed at an advanced stage, with hepatitis B or C viral infections and alcohol consumption identified as primary risk factors. Median survival rates were low. Neither HIV infection nor ALBI score grading had a significant impact on median survival.

12 May 2026 in Microbiome
Verified
Journal Article
Open access
PDF file
ACAngela Sofia Burkhart Colorado
Angela Sofia Burkhart Colorado
NNNichole M. Nusbacher
Nichole M. Nusbacher
JOJohn O’COnnor
John O’COnnor
TMTyson Marden
Tyson Marden
JHJanine A. Higgins
Janine A. Higgins
CLCatherine Lozupone
Catherine Lozupone
People living with HIV (PLWH) suffer from chronic inflammation even with effective antiretroviral therapy (ART). A high-fat, low-fiber western-type diet ha